Toll meets bacterial CpG-DNA - PubMed (original) (raw)

Review

Toll meets bacterial CpG-DNA

H Wagner. Immunity. 2001 May.

Free article

No abstract available

PubMed Disclaimer

Similar articles

• Bacterial CpG-DNA licenses TLR9.
  Bauer S, Wagner H. Bauer S, et al. Curr Top Microbiol Immunol. 2002;270:145-54. doi: 10.1007/978-3-642-59430-4_9. Curr Top Microbiol Immunol. 2002. PMID: 12467249 Review.
• CpG DNA: security code for host defense.
  Medzhitov R. Medzhitov R. Nat Immunol. 2001 Jan;2(1):15-6. doi: 10.1038/83121. Nat Immunol. 2001. PMID: 11135571 No abstract available.
• A Toll-like receptor recognizes bacterial DNA.
  Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. Hemmi H, et al. Nature. 2000 Dec 7;408(6813):740-5. doi: 10.1038/35047123. Nature. 2000. PMID: 11130078
• TLR9 signals after translocating from the ER to CpG DNA in the lysosome.
  Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT. Latz E, et al. Nat Immunol. 2004 Feb;5(2):190-8. doi: 10.1038/ni1028. Epub 2004 Jan 11. Nat Immunol. 2004. PMID: 14716310
• Role of Toll-like receptors in costimulating cytotoxic T cell responses.
  Schwarz K, Storni T, Manolova V, Didierlaurent A, Sirard JC, Röthlisberger P, Bachmann MF. Schwarz K, et al. Eur J Immunol. 2003 Jun;33(6):1465-70. doi: 10.1002/eji.200323919. Eur J Immunol. 2003. PMID: 12778463 Review.

Cited by

• Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools.
  Hasanzadeh A, Ebadati A, Dastanpour L, Aref AR, Sahandi Zangabad P, Kalbasi A, Dai X, Mehta G, Ghasemi A, Fatahi Y, Joshi S, Hamblin MR, Karimi M. Hasanzadeh A, et al. ACS Pharmacol Transl Sci. 2023 Nov 14;6(12):1758-1779. doi: 10.1021/acsptsci.3c00102. eCollection 2023 Dec 8. ACS Pharmacol Transl Sci. 2023. PMID: 38093832 Free PMC article. Review.
• Intraperitoneal injection of class A TLR9 agonist enhances anti-PD-1 immunotherapy in colorectal peritoneal metastases.
  Jiang T, Zhang H, Li Y, Jayakumar P, Liao H, Huang H, Billiar TR, Deng M. Jiang T, et al. JCI Insight. 2022 Oct 24;7(20):e160063. doi: 10.1172/jci.insight.160063. JCI Insight. 2022. PMID: 36278484 Free PMC article.
• Improved Cas9 activity by specific modifications of the tracrRNA.
  Scott T, Urak R, Soemardy C, Morris KV. Scott T, et al. Sci Rep. 2019 Nov 6;9(1):16104. doi: 10.1038/s41598-019-52616-5. Sci Rep. 2019. PMID: 31695072 Free PMC article.
• CRISPR-Cas9: A multifaceted therapeutic strategy for cancer treatment.
  Kaushik I, Ramachandran S, Srivastava SK. Kaushik I, et al. Semin Cell Dev Biol. 2019 Dec;96:4-12. doi: 10.1016/j.semcdb.2019.04.018. Epub 2019 May 4. Semin Cell Dev Biol. 2019. PMID: 31054324 Free PMC article. Review.
• Science and Bioethics of CRISPR-Cas9 Gene Editing: An Analysis Towards Separating Facts and Fiction.
  Cribbs AP, Perera SMW. Cribbs AP, et al. Yale J Biol Med. 2017 Dec 19;90(4):625-634. eCollection 2017 Dec. Yale J Biol Med. 2017. PMID: 29259526 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database